Piyush Durani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Piyush Durani has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Karen So
Renovo, Core Technology Facility, Manchester, Leicester, United Kingdom
3 shared publicationsMark W. J. Ferguson
3 shared publicationsTracey Mason
3 shared publications- David Leaper
Department of Surgery, University of Newcastle upon Tyne, Department of Clinical Sciences, University of Huddersfield, UK
2 shared publications Duncan A. McGrouther
2 shared publicationsJames Bush
Department of Plastic and Reconstructive Surgery, Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK
2 shared publications
Latest Publications
- 10 August 2012
- Published by BMJ in BMJ Quality & Safety
- Vol. 22 (1) , 65-71
Junior doctors and patient safety: evaluating knowledge, attitudes and perception of safety climate
Introduction Engagement of junior doctors in patient safety initiatives is high on the national agenda, but there is a lack of studies evaluating patient safety attitudes among junior doctors. Methods The Junior Doctor–Patient Safety Attitudes and Climate Questionnaire is a multidimensional scale created using items from already-validated scales and inclusion of new items based on further review. It consists of three subscales: ‘knowledge and training’ (10 items), ‘attitudes to patient safety’ (15 items) and ‘perception of workplace safety climate’ (15 items). This was disseminated to foundation trainees, general practice trainees and hospital core and speciality trainees via the Deanery distribution lists and responses were collected anonymously. Results A total of 527 complete responses were collected; although self-declared knowledge in patient safety concepts was high, there was less declared understanding of a ‘high reliability organisation’ (74% no/unsure) and the concept of active failures/latent conditions (60% no/unsure). The greatest agreement was demonstrated for the statement ‘Even the most experienced and competent doctors make errors’ (pConclusions This study demonstrates subtle differences in attitudes to patient safety among junior doctors of different grades and specialities. These should be taken into account when designing interventions to improve patient safety education and culture among junior doctors.
- 10 August 2012
- Published by BMJ in BMJ Quality & Safety
- Vol. 22 (1) , 65-71
Junior doctors and patient safety: evaluating knowledge, attitudes and perception of safety climate
Introduction Engagement of junior doctors in patient safety initiatives is high on the national agenda, but there is a lack of studies evaluating patient safety attitudes among junior doctors. Methods The Junior Doctor–Patient Safety Attitudes and Climate Questionnaire is a multidimensional scale created using items from already-validated scales and inclusion of new items based on further review. It consists of three subscales: ‘knowledge and training’ (10 items), ‘attitudes to patient safety’ (15 items) and ‘perception of workplace safety climate’ (15 items). This was disseminated to foundation trainees, general practice trainees and hospital core and speciality trainees via the Deanery distribution lists and responses were collected anonymously. Results A total of 527 complete responses were collected; although self-declared knowledge in patient safety concepts was high, there was less declared understanding of a ‘high reliability organisation’ (74% no/unsure) and the concept of active failures/latent conditions (60% no/unsure). The greatest agreement was demonstrated for the statement ‘Even the most experienced and competent doctors make errors’ (pConclusions This study demonstrates subtle differences in attitudes to patient safety among junior doctors of different grades and specialities. These should be taken into account when designing interventions to improve patient safety education and culture among junior doctors.
- 1 July 2011
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 128 (1) , 163-172
Avotermin for Scar Improvement following Scar Revision Surgery: A Randomized, Double-Blind, Within-Patient, Placebo-Controlled, Phase II Clinical Trial
Skin scarring is associated with psychosocial distress and has a negative effect on quality of life. The transforming growth factor (TGF)-β family of cytokines plays a key role in scarring. TGF-β3 improves scar appearance in a range of mammalian species. This study was performed to assess the efficacy of intradermal avotermin (TGF-β3) for the improvement of scar appearance following scar revision surgery. Sixty patients (35 men and 25 women; age, 19 to 78 years; 53 Caucasians; scar length, 5 to 21 cm) received intradermal avotermin (200 ng/100 μl/linear cm wound margin) and placebo to outer wound segments immediately after, and again 24 hours after, complete (group 1) or staged (group 2) scar revision surgery. A within-patient design was chosen to control for interindividual factors that affect scarring. The primary efficacy variable was a total scar score derived from a visual analogue scale, scored by a lay panel from standardized photographs from months 1 through 7 following treatment. : Primary endpoint data from the combined surgical groups showed that avotermin significantly improved scar appearance compared with placebo (total scar score difference, 21.93 mm; p = 0.04). Profilometry showed a greater reduction in scar surface area from baseline with avotermin treatment compared with placebo, significant in group 2 at months 7 and 12 (difference, 41.99 mm and 25.85 mm, respectively; p = 0.03 for both comparisons). Histologic analysis from group 2 showed that, compared with placebo treatment, collagen organization in avotermin-treated scars more closely resembled normal skin in 14 of 19 cases. Avotermin was well tolerated. Avotermin administration following scar revision surgery is well tolerated and significantly improves scar appearance compared with placebo. Therapeutic, I.(Figure is included in full-text article.).
- 1 July 2011
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 128 (1) , 163-172
Avotermin for Scar Improvement following Scar Revision Surgery: A Randomized, Double-Blind, Within-Patient, Placebo-Controlled, Phase II Clinical Trial
Skin scarring is associated with psychosocial distress and has a negative effect on quality of life. The transforming growth factor (TGF)-β family of cytokines plays a key role in scarring. TGF-β3 improves scar appearance in a range of mammalian species. This study was performed to assess the efficacy of intradermal avotermin (TGF-β3) for the improvement of scar appearance following scar revision surgery. Sixty patients (35 men and 25 women; age, 19 to 78 years; 53 Caucasians; scar length, 5 to 21 cm) received intradermal avotermin (200 ng/100 μl/linear cm wound margin) and placebo to outer wound segments immediately after, and again 24 hours after, complete (group 1) or staged (group 2) scar revision surgery. A within-patient design was chosen to control for interindividual factors that affect scarring. The primary efficacy variable was a total scar score derived from a visual analogue scale, scored by a lay panel from standardized photographs from months 1 through 7 following treatment. : Primary endpoint data from the combined surgical groups showed that avotermin significantly improved scar appearance compared with placebo (total scar score difference, 21.93 mm; p = 0.04). Profilometry showed a greater reduction in scar surface area from baseline with avotermin treatment compared with placebo, significant in group 2 at months 7 and 12 (difference, 41.99 mm and 25.85 mm, respectively; p = 0.03 for both comparisons). Histologic analysis from group 2 showed that, compared with placebo treatment, collagen organization in avotermin-treated scars more closely resembled normal skin in 14 of 19 cases. Avotermin was well tolerated. Avotermin administration following scar revision surgery is well tolerated and significantly improves scar appearance compared with placebo. Therapeutic, I.(Figure is included in full-text article.).
- 1 April 2011
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 127 (4) , 1744-1745
Patient Assessments of Scarring: Patient-Reported Impact of Scars Measure or Patient Scar Assessment Questionnaire?
- 1 April 2011
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 127 (4) , 1744-1745
Patient Assessments of Scarring: Patient-Reported Impact of Scars Measure or Patient Scar Assessment Questionnaire?
- 1 November 2010
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 126 (5) , 1604-1615
Scar-Improving Efficacy of Avotermin Administered into the Wound Margins of Skin Incisions as Evaluated by a Randomized, Double-Blind, Placebo-Controlled, Phase II Clinical Trial
The authors report on a prospective, randomized, placebo-controlled phase II trial to investigate avotermin (transforming growth factor beta-3) for reducing scarring resulting from acute incised skin wounds. Seventy-one healthy male subjects (18 to 45 years) received avotermin at 50 or 200 ng/100 μl/linear centimeter of wound margin. Subjects received three standardized 1-cm incisional wounds on the inner aspect of each upper arm. Wounds were randomized to receive (into each margin): no injection (standard wound care only), one intradermal injection of avotermin or placebo (immediately before surgery), or two injections of avotermin or placebo (immediately before surgery and 24 hours later). The primary efficacy variable was a 10-cm visual analog scale score, which assessed how closely scars resembled normal skin, administered at month 12 by an independent external scar assessment panel (a panel of lay public individuals). Avotermin at 200 ng/100 μl/linear centimeter, administered once or twice, achieved significant improvements in scar appearance compared with controls (p<0.02 for all comparisons). The 50-ng dose, administered twice, achieved significant improvements in scar appearance versus placebo (p=0.043). Treatment was well tolerated. These results confirm that avotermin is the first of a new class of regenerative medicines that reduce scarring when administered once or twice to the approximated margins of acute skin incisions.
- 1 November 2010
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 126 (5) , 1604-1615
Scar-Improving Efficacy of Avotermin Administered into the Wound Margins of Skin Incisions as Evaluated by a Randomized, Double-Blind, Placebo-Controlled, Phase II Clinical Trial
The authors report on a prospective, randomized, placebo-controlled phase II trial to investigate avotermin (transforming growth factor beta-3) for reducing scarring resulting from acute incised skin wounds. Seventy-one healthy male subjects (18 to 45 years) received avotermin at 50 or 200 ng/100 μl/linear centimeter of wound margin. Subjects received three standardized 1-cm incisional wounds on the inner aspect of each upper arm. Wounds were randomized to receive (into each margin): no injection (standard wound care only), one intradermal injection of avotermin or placebo (immediately before surgery), or two injections of avotermin or placebo (immediately before surgery and 24 hours later). The primary efficacy variable was a 10-cm visual analog scale score, which assessed how closely scars resembled normal skin, administered at month 12 by an independent external scar assessment panel (a panel of lay public individuals). Avotermin at 200 ng/100 μl/linear centimeter, administered once or twice, achieved significant improvements in scar appearance compared with controls (p<0.02 for all comparisons). The 50-ng dose, administered twice, achieved significant improvements in scar appearance versus placebo (p=0.043). Treatment was well tolerated. These results confirm that avotermin is the first of a new class of regenerative medicines that reduce scarring when administered once or twice to the approximated margins of acute skin incisions.
- 1 June 2009
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 62 (6) , 713-720
Current scales for assessing human scarring: A review
- 1 June 2009
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 62 (6) , 713-720
Current scales for assessing human scarring: A review
- 1 May 2009
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 123 (5) , 1481-1489
The Patient Scar Assessment Questionnaire: A Reliable and Valid Patient-Reported Outcomes Measure for Linear Scars
There is a lack of rigorously validated patient-based outcomes measures of scarring. The aim of this study was to construct such a scale and demonstrate reliability and validity by applying the scale in a wide range of scarring samples. The Patient Scar Assessment Questionnaire with five subscales (i.e., Appearance, Symptoms, Consciousness, Satisfaction with Appearance, and Satisfaction with Symptoms) was constructed using multiple categorical response items. The Patient Scar Assessment Questionnaire was applied to various surgical samples (total scar assessments n = 667) at months 3, 6, and 12 after surgery (and preoperatively in the scar revision group) and tested for internal consistency, test-retest reliability, convergent validity, known group differences, and sensitivity, against widely accepted criteria from psychometric measurement science. Subscales showed high internal consistency (Cronbach alpha, 0.73 to 0.93), except the Symptoms subscale. Test-retest reliability was high across all subscales (intraclass correlation coefficient, 0.74 to 0.87) across all groups except the scar revision group. Change in Patient Scar Assessment Questionnaire scores was significant between months 3 and 6 postoperatively (p < 0.001) and subscales demonstrated known group differences (p < 0.001). Convergent validity was demonstrated by significant moderate correlations with various measures of similar constructs (r = 0.26 to 0.61, p < 0.001). The Patient Scar Assessment Questionnaire is a reliable and valid measure of the patient's perception of scarring, although the Symptoms subscale requires further refinement. Subscales can be used independently of each other to allow assessment of scar change in specific domains.
- 1 May 2009
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 123 (5) , 1481-1489
The Patient Scar Assessment Questionnaire: A Reliable and Valid Patient-Reported Outcomes Measure for Linear Scars
There is a lack of rigorously validated patient-based outcomes measures of scarring. The aim of this study was to construct such a scale and demonstrate reliability and validity by applying the scale in a wide range of scarring samples. The Patient Scar Assessment Questionnaire with five subscales (i.e., Appearance, Symptoms, Consciousness, Satisfaction with Appearance, and Satisfaction with Symptoms) was constructed using multiple categorical response items. The Patient Scar Assessment Questionnaire was applied to various surgical samples (total scar assessments n = 667) at months 3, 6, and 12 after surgery (and preoperatively in the scar revision group) and tested for internal consistency, test-retest reliability, convergent validity, known group differences, and sensitivity, against widely accepted criteria from psychometric measurement science. Subscales showed high internal consistency (Cronbach alpha, 0.73 to 0.93), except the Symptoms subscale. Test-retest reliability was high across all subscales (intraclass correlation coefficient, 0.74 to 0.87) across all groups except the scar revision group. Change in Patient Scar Assessment Questionnaire scores was significant between months 3 and 6 postoperatively (p < 0.001) and subscales demonstrated known group differences (p < 0.001). Convergent validity was demonstrated by significant moderate correlations with various measures of similar constructs (r = 0.26 to 0.61, p < 0.001). The Patient Scar Assessment Questionnaire is a reliable and valid measure of the patient's perception of scarring, although the Symptoms subscale requires further refinement. Subscales can be used independently of each other to allow assessment of scar change in specific domains.
- 1 April 2009
- Published by Elsevier in The Lancet
- Vol. 373 (9671) , 1264-1274
Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies
- 1 April 2009
- Published by Elsevier in The Lancet
- Vol. 373 (9671) , 1264-1274
Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies
- 1 September 2008
- Published by SAGE Publications in The International Journal of Lower Extremity Wounds
- Vol. 7 (3) , 160-168
Avotermin: A Novel Antiscarring Agent
Published literature shows that both physicians and their patients are highly concerned about scarring, even relatively minor scars and those that can be concealed by clothing. Furthermore, both patients and their physicians value any opportunities to improve or minimize scarring. While a range of treatment paradigms have been evaluated, no single therapy has been adopted as a universally accepted standard of care and, currently, there are no marketed pharmaceuticals for the prophylactic reduction of scarring. Many of the available treatments are used empirically and most have not been evaluated in robust prospective, randomized, controlled clinical trials. To address this unmet medical need, translational research into the molecular mechanisms of scarring has led to the discovery and commercial development of a new class of prophylactic medicines that promote the regeneration of normal skin and improve scar appearance. Avotermin, the first agent identified in this class, is the clinical application of human recombinant transforming growth factor β3 (TGFβ3), a key protein involved in scar-free healing observed in embryos. Controlled, double-blind, randomized phase I/II clinical studies have shown that avotermin, administered as an intradermal injection at the time of surgery, leads to both short-term and longer-term (at ≥12 months) improvements in the appearance of scars compared with placebo and standard wound care.
- 1 September 2008
- Published by SAGE Publications in The International Journal of Lower Extremity Wounds
- Vol. 7 (3) , 160-168
Avotermin: A Novel Antiscarring Agent
Published literature shows that both physicians and their patients are highly concerned about scarring, even relatively minor scars and those that can be concealed by clothing. Furthermore, both patients and their physicians value any opportunities to improve or minimize scarring. While a range of treatment paradigms have been evaluated, no single therapy has been adopted as a universally accepted standard of care and, currently, there are no marketed pharmaceuticals for the prophylactic reduction of scarring. Many of the available treatments are used empirically and most have not been evaluated in robust prospective, randomized, controlled clinical trials. To address this unmet medical need, translational research into the molecular mechanisms of scarring has led to the discovery and commercial development of a new class of prophylactic medicines that promote the regeneration of normal skin and improve scar appearance. Avotermin, the first agent identified in this class, is the clinical application of human recombinant transforming growth factor β3 (TGFβ3), a key protein involved in scar-free healing observed in embryos. Controlled, double-blind, randomized phase I/II clinical studies have shown that avotermin, administered as an intradermal injection at the time of surgery, leads to both short-term and longer-term (at ≥12 months) improvements in the appearance of scars compared with placebo and standard wound care.
- 28 June 2008
- Published by Wiley in International Wound Journal
- Vol. 5 (3) , 376-387
Povidone–iodine: use in hand disinfection, skin preparation and antiseptic irrigation
Iodine and its antibacterial properties have been used for the prevention or management of wound infections for over 150 years. However, the use of solutions (tincture) of iodine has been replaced by the widespread use of povidone–iodine, a water‐soluble compound, which is a combination of molecular iodine and polyvinylpyrrolidone. The resultant broad spectrum of antimicrobial activity is well documented and its efficacy, particularly in relation to resistant micro‐organisms such as methicillin‐resistant Staphylococcus aureus, has been shown. In the clinical environment, there is no general agreement regarding the ‘best’ antiseptic and the practice varies widely. This article reviews the studies that have assessed the efficacy of povidone–iodine in hand disinfection and skin preparation and its use as an antiseptic irrigant. Although there is a distinct lack of well‐designed, randomised controlled trials evaluating antiseptic efficacy, selection should be based on the next best available evidence. This evidence suggests that the use of povidone–iodine as an agent of choice is dependent on the clinical need but is also likely to be influenced by personal preference.
- 28 June 2008
- Published by Wiley in International Wound Journal
- Vol. 5 (3) , 376-387
Povidone–iodine: use in hand disinfection, skin preparation and antiseptic irrigation
Iodine and its antibacterial properties have been used for the prevention or management of wound infections for over 150 years. However, the use of solutions (tincture) of iodine has been replaced by the widespread use of povidone–iodine, a water‐soluble compound, which is a combination of molecular iodine and polyvinylpyrrolidone. The resultant broad spectrum of antimicrobial activity is well documented and its efficacy, particularly in relation to resistant micro‐organisms such as methicillin‐resistant Staphylococcus aureus, has been shown. In the clinical environment, there is no general agreement regarding the ‘best’ antiseptic and the practice varies widely. This article reviews the studies that have assessed the efficacy of povidone–iodine in hand disinfection and skin preparation and its use as an antiseptic irrigant. Although there is a distinct lack of well‐designed, randomised controlled trials evaluating antiseptic efficacy, selection should be based on the next best available evidence. This evidence suggests that the use of povidone–iodine as an agent of choice is dependent on the clinical need but is also likely to be influenced by personal preference.
- 20 May 2008
- Published by Wiley in International Wound Journal
- Vol. 5 (2) , 361-368
Topical antimicrobial therapy of chronic wounds healing by secondary intention using iodine products
All open wounds healing by secondary intention are contaminated by bacteria and in chronic wounds this can progress through colonisation to invasive infection. Iodine products reduce bacterial load and are active against most species of micro‐organisms, and certainly those encountered in chronic wound care. This review evaluates the use of iodine products in chronic wound care including povidone‐iodine solutions and cadexomer iodine. Antiseptics containing iodine are relatively cheap, resistance is unknown and concerns about systemic toxicity are probably overstated. More widespread use of these agents as topical anti‐microbials in chronic wound care should be considered to reduce the need for systemic antibiotics when colonisation has progressed to invasive infection with systemic signs.
- 20 May 2008
- Published by Wiley in International Wound Journal
- Vol. 5 (2) , 361-368
Topical antimicrobial therapy of chronic wounds healing by secondary intention using iodine products
All open wounds healing by secondary intention are contaminated by bacteria and in chronic wounds this can progress through colonisation to invasive infection. Iodine products reduce bacterial load and are active against most species of micro‐organisms, and certainly those encountered in chronic wound care. This review evaluates the use of iodine products in chronic wound care including povidone‐iodine solutions and cadexomer iodine. Antiseptics containing iodine are relatively cheap, resistance is unknown and concerns about systemic toxicity are probably overstated. More widespread use of these agents as topical anti‐microbials in chronic wound care should be considered to reduce the need for systemic antibiotics when colonisation has progressed to invasive infection with systemic signs.